Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Jonathan PoirierSophie GodemelAurélie MourotSolange GrunenwaldHarold J OlneyXuan Kim LeAndrea Z LaCroixPhilippe J CaronIsabelle BourdeauPublished in: The Journal of clinical endocrinology and metabolism (2023)
Mitotane therapy is frequently associated with new onset of central hypothyroidism with a prevalence of 95.5%. Most cases occurred in the first year of treatment. Partial or full recovery of thyroid function occurs in 65.4% of cases. This study supports the importance of systematic monitoring of TSH and free T4 levels during and following discontinuation of mitotane therapy.